Quarterly ResultMay 15, 2026, 04:53 PM
Liminatus Pharma Q1 Net Loss $(1.12)M; Going Concern Doubt
AI Summary
Liminatus Pharma reported a net loss of $(1.12) million for Q1 2026, significantly higher than $(0.33) million in Q1 2025, driven by increased general & administrative and new research & development expenses. The company raised approximately $3.44 million in net proceeds from a public offering in February 2026, which improved its cash position to $1.91 million and reduced its stockholders' deficit. However, management has concluded there is substantial doubt about its ability to continue as a going concern, and the company faces multiple Nasdaq listing compliance issues, including minimum bid price and market value requirements.
Key Highlights
- Net loss increased to $(1.12) million for Q1 2026 from $(0.33) million in Q1 2025.
- Cash balance rose to $1.91 million as of March 31, 2026, from $0.34 million at Dec 31, 2025.
- Total stockholders' deficit improved to $(0.13) million from $(9.81) million.
- Raised approximately $3.44 million net proceeds from a public offering in February 2026.
- Settled $7.36 million in settlement payable by issuing 4,000,000 common shares.
- Faces Nasdaq non-compliance for minimum bid price ($1) and market value rules.
- Management identified substantial doubt about the company's ability to continue as a going concern.
- Research and development expenses were $400,000 in Q1 2026, up from $0 in Q1 2025.
Price Impact
More from LIMN